Centers for Disease Control and Prevention/Health Resources and Services Administration (CDC/HRSA) Advisory Committee on HIV and STD Prevention and Treatment, 75436 [E8-29325]

Download as PDF 75436 Federal Register / Vol. 73, No. 239 / Thursday, December 11, 2008 / Notices Executive Order 13179, issued on December 7, 2000, delegated authorities assigned to ‘‘the President’’ under the Act to the Departments of Labor, Health and Human Services, Energy and Justice. The Department of Health and Human Services (DHHS) was delegated the responsibility of establishing methods for estimating radiation doses received by eligible claimants with cancer applying for compensation. NIOSH is applying the following methods to estimate the radiation doses of individuals applying for compensation. In performance of its dose reconstruction responsibilities, under the Act, NIOSH is providing voluntary interview opportunities to claimants (or their survivors) individually and providing them with the opportunity to assist NIOSH in documenting the work history of the employee by characterizing the actual work tasks performed. In addition, NIOSH and the claimant may identify incidents that may have resulted in undocumented radiation exposures, characterizing radiological protection and monitoring practices, and identify co-workers and other witnesses as may be necessary to confirm undocumented information. In this process, NIOSH uses a computer assisted telephone interview (CATI) system, which allows interviews to be conducted more efficiently and quickly as opposed to a paper-based interview instrument. Both interviews are voluntary and failure to participate in either or both interviews will not have a negative effect on the claim, although voluntary participation may assist the claimant by adding important information that may not be otherwise available. NIOSH uses the data collected in this process to complete an individual dose reconstruction that accounts, as fully as possible, for the radiation dose incurred by the employee in the line of duty for DOE nuclear weapons production programs. After dose reconstruction, NIOSH also performs a brief, voluntary final interview with the claimant to explain the results and to allow the claimant to confirm or question the records NIOSH has compiled. This will also be the final opportunity for the claimant to supplement the dose reconstruction record. At the conclusion of the dose reconstruction process, the claimant submits a form to confirm that the claimant has no further information to provide to NIOSH about the claim at this time. The form notifies the claimant that signing the form allows NIOSH to forward a dose reconstruction report to Department of Labor (DOL) and to the claimant, and closes the record on data used for the dose reconstruction. Signing this form does not indicate that the claimant agrees with the outcome of the dose reconstruction. The dose reconstruction results will be supplied to the claimant and to the DOL, the agency that will utilize them as one part of its determination of whether the claimant is eligible for compensation under the Act. There is no cost to respondents other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondent Number of responses per respondent Average burden (in hours) Total response burden hours Initial interview ................................................................................................. Conclusion Form .............................................................................................. 4,200 8,400 1 1 1 5/60 4,200 700 Total .......................................................................................................... ........................ ........................ ........................ 4,900 Dated: December 5, 2008. Maryam I. Daneshvar, Acting Reports Clearance Officer, Office of the Chief Science Officer, Centers for Disease Control and Prevention. [FR Doc. E8–29322 Filed 12–10–08; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention mstockstill on PROD1PC66 with NOTICES Centers for Disease Control and Prevention/Health Resources and Services Administration (CDC/HRSA) Advisory Committee on HIV and STD Prevention and Treatment This gives notice under the Federal Advisory Committee Act (Pub. L. 92– 463) of October 6, 1972, that the CDC/ HRSA Advisory Committee on HIV and STD Prevention and Treatment, Department of Health and Human Services, has been renewed for a 2-year period through November 25, 2010. VerDate Aug<31>2005 17:27 Dec 10, 2008 Jkt 217001 FOR FURTHER INFORMATION CONTACT: contact Kevin Fenton, M.D., Ph.D., Executive Secretary, CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment, Department of Health and Human Services, 1600 Clifton Road, NE., Mailstop E07, Atlanta, Georgia 30333, telephone (404) 639–8000 or fax (404) 639–8600. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: December 4, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–29325 Filed 12–10–08; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2007–D–0429] (formerly Docket No. 2007D–0496) Draft Guidance for Industry on Questions and Answers Regarding the Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Revision 1; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance entitled ‘‘Questions and Answers Regarding the Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug E:\FR\FM\11DEN1.SGM 11DEN1

Agencies

[Federal Register Volume 73, Number 239 (Thursday, December 11, 2008)]
[Notices]
[Page 75436]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-29325]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Centers for Disease Control and Prevention/Health Resources and 
Services Administration (CDC/HRSA) Advisory Committee on HIV and STD 
Prevention and Treatment

    This gives notice under the Federal Advisory Committee Act (Pub. L. 
92-463) of October 6, 1972, that the CDC/HRSA Advisory Committee on HIV 
and STD Prevention and Treatment, Department of Health and Human 
Services, has been renewed for a 2-year period through November 25, 
2010.

FOR FURTHER INFORMATION CONTACT: contact Kevin Fenton, M.D., Ph.D., 
Executive Secretary, CDC/HRSA Advisory Committee on HIV and STD 
Prevention and Treatment, Department of Health and Human Services, 1600 
Clifton Road, NE., Mailstop E07, Atlanta, Georgia 30333, telephone 
(404) 639-8000 or fax (404) 639-8600.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

    Dated: December 4, 2008.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E8-29325 Filed 12-10-08; 8:45 am]
BILLING CODE 4163-18-P